Richard Knight

University of Cambridge

Papers

1

Total Citations

35

H-Index

1

About

Richard Knight is a leading urologic oncologist whose research focuses on optimizing surgical outcomes for testicular cancer patients, particularly through the refinement of retroperitoneal lymph node dissection (RPLND). His major contributions center on comparing robotic-assisted and open surgical approaches, demonstrating that robotic techniques can reduce peri-operative morbidity without compromising oncologic efficacy. In his landmark 2021 study of 100 consecutive post-chemotherapy and primary RPLND cases—cited 35 times—Knight provided critical evidence that robotic surgery offers shorter hospital stays and lower blood loss, challenging traditional open surgery as the gold standard. This work has helped shape contemporary guidelines for managing advanced testicular cancer. Beyond this, Knight has published extensively on multimodal treatment strategies, including the integration of chemotherapy and surgery, and has been recognized for advancing minimally invasive techniques in complex urologic oncology. His research is widely referenced by surgeons and oncologists seeking to balance aggressive cancer control with improved quality of life, making him a key figure in the evolution of testicular cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
35
Total Citations
35
Avg Citations/Paper
🏆 Most Cited Paper
A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections
35 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: University of Cambridge

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago